Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

• * Subject is ≥ 18 years at the time of signing informed consent;
• * Confirmed malignant hematologic disease or lymphoid malignancy that has relapsed or is refractory to standard therapy and has exhausted all available therapies;
• * Presence of measurable or evaluable disease;
• * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;
• * Contraceptives or other approved avoidance of pregnancy measures
• * Allogeneic stem cell transplant recipient presenting with graft versus host disease (GVHD) either active or requiring immunosuppression;
• * Concomitantly taking anti-cancer therapy (bisphosphonates are permitted);
• * Undergone major surgery ≤ 2 weeks prior to starting study drug;
• * Evidence of mucosal or internal bleeding;
• * Impaired cardiac function or conduction defect;
• * Concurrent severe and/or uncontrolled medical conditions